Article
Genetic polymorphisms of flavin monooxygenase 3 in sulindac-induced regression of colorectal adenomas in familial adenomatous polyposis.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 1 Oct 2005
Hisamuddin Irfan M, Wehbi Mohammad A, Schmotzer Brian, Easley Kirk A, Hylind Linda M, Giardiello Francis M, Yang Vincent W
Abstract excerpt
Sulindac is a nonsteroidal antiinflammatory drug with a chemopreventive effect in patients with familial adenomatous polyposis (FAP). In vivo, the active form of sulindac is sulindac sulfide, which is inactivated by the hepatic microsomal enzyme, flavin monooxygenase 3 (FMO3). In humans, numerous polymorphisms exist in FMO3, which alter enzymatic activity and subsequent substrate metabolism. We recently showed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.